Abstract
Language | English |
---|---|
Article number | ACVD-1047 |
Pages | 700-711 |
Number of pages | 12 |
Journal | Archives of Cardiovascular Diseases |
Volume | 110 |
Issue number | 12 |
Early online date | 31 Oct 2017 |
DOIs | |
Publication status | E-pub ahead of print - 31 Oct 2017 |
Fingerprint
Keywords
- Atherosclerosis, Transmembrane proteins, TNFα, Biomarker, TACE
Cite this
}
Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events. / El Chemaly, Melody; McGilligan, V. E.; Gibson, Mark; Clauss, Matthias ; Watterson, Steven; Alexander, H. Denis; Bjourson, AJ; Peace, Aaron.
In: Archives of Cardiovascular Diseases, Vol. 110, No. 12, ACVD-1047, 31.10.2017, p. 700-711.Research output: Contribution to journal › Article
TY - JOUR
T1 - Role of tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and associated proteins in coronary artery disease and cardiac events
AU - El Chemaly, Melody
AU - McGilligan, V. E.
AU - Gibson, Mark
AU - Clauss, Matthias
AU - Watterson, Steven
AU - Alexander, H. Denis
AU - Bjourson, AJ
AU - Peace, Aaron
PY - 2017/10/31
Y1 - 2017/10/31
N2 - Summary Tumour necrosis factor alpha converting enzyme (TACE/ADAM17) is a member of the A disintegrin and metalloproteinase (ADAM) family of ectodomain shedding proteinases. It regulates many inflammatory processes by cleaving several transmembrane proteins, including tumour necrosis factor alpha (TNFalpha) and its receptors tumour necrosis factor alpha receptor 1 and tumour necrosis factor alpha receptor 2. There is evidence that TACE is involved in several TACE inflammatory diseases, such as ischaemia, heart failure, arthritis, atherosclerosis, diabetes and cancer as well as neurological and immune diseases. This review summarizes the latest discoveries regarding the mechanism of action and regulation of TACE. It also focuses on the role of TACE in atherosclerosis and coronary artery disease (CAD), highlighting clinical studies that have investigated its expression and protein activity. The multitude of substrates cleaved by TACE make this enzyme an attractive target for therapy and a candidate for biomarker research and development in CAD.
AB - Summary Tumour necrosis factor alpha converting enzyme (TACE/ADAM17) is a member of the A disintegrin and metalloproteinase (ADAM) family of ectodomain shedding proteinases. It regulates many inflammatory processes by cleaving several transmembrane proteins, including tumour necrosis factor alpha (TNFalpha) and its receptors tumour necrosis factor alpha receptor 1 and tumour necrosis factor alpha receptor 2. There is evidence that TACE is involved in several TACE inflammatory diseases, such as ischaemia, heart failure, arthritis, atherosclerosis, diabetes and cancer as well as neurological and immune diseases. This review summarizes the latest discoveries regarding the mechanism of action and regulation of TACE. It also focuses on the role of TACE in atherosclerosis and coronary artery disease (CAD), highlighting clinical studies that have investigated its expression and protein activity. The multitude of substrates cleaved by TACE make this enzyme an attractive target for therapy and a candidate for biomarker research and development in CAD.
KW - Atherosclerosis, Transmembrane proteins, TNFα, Biomarker, TACE
U2 - 10.1016/j.acvd.2017.08.002
DO - 10.1016/j.acvd.2017.08.002
M3 - Article
VL - 110
SP - 700
EP - 711
JO - Archives of Cardiovascular Diseases
T2 - Archives of Cardiovascular Diseases
JF - Archives of Cardiovascular Diseases
SN - 1875-2136
IS - 12
M1 - ACVD-1047
ER -